Literature DB >> 23031661

Histidine-tryptophan-ketoglutarate and University of Wisconsin solution demonstrate equal effectiveness in the preservation of human pancreata intended for islet isolation: a large-scale, single-center experience.

Daniel H Paushter1, Meirigeng Qi, Kirstie K Danielson, Tricia A Harvat, Katie Kinzer, Barbara Barbaro, Sonny Patel, Sarah Z Hassan, Jose Oberholzer, Yong Wang.   

Abstract

We previously reported a small-scale study on the efficacy of histidine-tryptophan-ketoglutarate (HTK) solution versus University of Wisconsin (UW) solution on pancreas preservation for islet isolation. In this large-scale, retrospective analysis (n = 252), we extend our initial description of the impact of HTK on islet isolation outcomes and include pancreatic digestion efficacy, purification outcomes, and islet size distribution. Multivariable linear regression analysis, adjusted for donor age, sex, BMI, cold ischemia time, and enzyme, demonstrated similar results for the HTK group (n = 95) and the UW group (n = 157), including postpurification islet yields (HTK: 289,702 IEQ vs. UW: 283,036 IEQ; p = 0.76), percentage of digested pancreatic tissue (HTK: 66.9% vs. UW: 64.1%; p = 0.18), and islet loss from postdigestion to postpurification (HTK: 24,972 IEQ vs. UW: 39,551 IEQ; p = 0.38). Changes in islet size between the postdigestion and postpurification stages were comparable within each islet size category for HTK and UW (p = 0.14-0.99). Tissue volume distribution across purification fractions and islet purity in the top fractions were similar between the groups; however, the HTK group had significantly higher islet purity in the middle fractions (p = 0.003-0.008). Islet viability and stimulation indices were also similar between the HTK and the UW groups. In addition, we analyzed a small sample of patients transplanted either with HTK (n = 7) or UW (n = 8) preserved islets and found no significant differences in posttransplant HbA1c, β-score, and frequency of insulin independence. This study demonstrates that HTK and UW solutions offer comparable pancreas preservation for islet transplantation. More in vivo islet outcome data are needed for a complete analysis of the effects of HTK on islet transplantation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23031661      PMCID: PMC3759240          DOI: 10.3727/096368912X657332

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  29 in total

1.  Pancreas and islet transplantation.

Authors:  N J London; P R Bell
Journal:  Br J Surg       Date:  1992-01       Impact factor: 6.939

2.  Histidine-Tryptophan-Ketoglutarate (HTK) is associated with reduced graft survival in deceased donor livers, especially those donated after cardiac death.

Authors:  Z A Stewart; A M Cameron; A L Singer; R A Montgomery; D L Segev
Journal:  Am J Transplant       Date:  2008-11-27       Impact factor: 8.086

3.  Histidine-tryptophan-ketoglutarate (HTK) is associated with reduced graft survival of deceased donor kidney transplants.

Authors:  Z A Stewart; B E Lonze; D S Warren; N N Dagher; A L Singer; R A Montgomery; D L Segev
Journal:  Am J Transplant       Date:  2009-03-03       Impact factor: 8.086

4.  Histidine-tryptophan-ketoglutarate (HTK) is associated with reduced graft survival in pancreas transplantation.

Authors:  Z A Stewart; A M Cameron; A L Singer; N N Dagher; R A Montgomery; D L Segev
Journal:  Am J Transplant       Date:  2008-11-04       Impact factor: 8.086

5.  Histidine-tryptophan-ketoglutarate for pancreas allograft preservation: the Indiana University experience.

Authors:  J A Fridell; R S Mangus; J A Powelson
Journal:  Am J Transplant       Date:  2010-03-26       Impact factor: 8.086

6.  Myocardial protection.

Authors:  H J Bretschneider
Journal:  Thorac Cardiovasc Surg       Date:  1980-10       Impact factor: 1.827

7.  Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen.

Authors:  A M Shapiro; J R Lakey; E A Ryan; G S Korbutt; E Toth; G L Warnock; N M Kneteman; R V Rajotte
Journal:  N Engl J Med       Date:  2000-07-27       Impact factor: 91.245

8.  Comparison of histidine-tryptophan-ketoglutarate solution and University of Wisconsin solution for organ preservation in clinical pancreas transplantation.

Authors:  Jonathan A Fridell; Avinash Agarwal; Martin L Milgrom; William C Goggins; Philip Murdock; Mark D Pescovitz
Journal:  Transplantation       Date:  2004-04-27       Impact factor: 4.939

9.  Histidine-tryptophan-ketoglutarate versus University of Wisconsin solution in living donor liver transplantation: results of a prospective study.

Authors:  Giuliano Testa; Massimo Malagó; Silvio Nadalin; Boris Treptow; Andreas Paul; Andrea Frilling; Christoph E Broelsch
Journal:  Liver Transpl       Date:  2003-08       Impact factor: 5.799

10.  Greater hemodynamic instability with histidine-tryptophan-ketoglutarate solution than University of Wisconsin solution during the reperfusion period in living donor liver transplantation.

Authors:  J S Ko; G S Kim; M S Gwak; M Yang; H K Kim; B S Shin; J K Kim; S K Lee
Journal:  Transplant Proc       Date:  2008-12       Impact factor: 1.066

View more
  5 in total

1.  Comparison of New Preservation Solutions, HN-1 and University of Wisconsin Solution, in Pancreas Preservation for Porcine Islet Isolation.

Authors:  Akihiro Katayama; Hirofumi Noguchi; Takashi Kuise; Atsuko Nakatsuka; Daisho Hirota; Hitomi Usui Kataoka; Takashi Kawai; Kentaro Inoue; Noriko Imagawa; Issei Saitoh; Yasufumi Noguchi; Masami Watanabe; Jun Wada; Toshiyoshi Fujiwara
Journal:  Cell Med       Date:  2013-10-21

Review 2.  Islet transplantation in type 1 diabetes: ongoing challenges, refined procedures, and long-term outcome.

Authors:  A M James Shapiro
Journal:  Rev Diabet Stud       Date:  2012-12-28

3.  Combining Donor Characteristics with Immunohistological Data Improves the Prediction of Islet Isolation Success.

Authors:  Zuzana Berkova; Frantisek Saudek; Peter Girman; Klara Zacharovova; Jan Kriz; Eva Fabryova; Ivan Leontovyc; Tomas Koblas; Lucie Kosinova; Tomas Neskudla; Ema Vavrova; David Habart; Sarka Loukotova; Martina Zahradnicka; Kvetoslav Lipar; Ludek Voska; Jelena Skibova
Journal:  J Diabetes Res       Date:  2016-10-10       Impact factor: 4.011

4.  Improved yield of canine islet isolation from deceased donors.

Authors:  Stephen Harrington; S Janette Williams; Vern Otte; Sally Barchman; Cheryl Jones; Karthik Ramachandran; Lisa Stehno-Bittel
Journal:  BMC Vet Res       Date:  2017-08-22       Impact factor: 2.741

Review 5.  Anti-Oxidative Therapy in Islet Cell Transplantation.

Authors:  Natsuki Eguchi; Kimia Damyar; Michael Alexander; Donald Dafoe; Jonathan R T Lakey; Hirohito Ichii
Journal:  Antioxidants (Basel)       Date:  2022-05-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.